Literature DB >> 19894110

Reductions in use of hormone replacement therapy: effects on Swedish breast cancer incidence trends only seen after several years.

Mats Lambe1, Annette Wigertz, Marit Holmqvist, Jan Adolfsson, Carola Bardage, Tommy Fornander, Per Karlsson, Viveca Odlind, Ingemar Persson, Johan Ahlgren, Leif Bergkvist.   

Abstract

Studies from Western countries have found evidence of a recent decline in breast cancer incidence rates in postmenopausal women, findings which have been hypothesized to reflect a reduced use of hormonal replacement therapy (HRT). We examined breast cancer incidence trends in Sweden between 1997 and 2007, a period characterized by a drop in the use of HRT. Incidence trends were assessed using data from three population-based Regional Clinical Registries on breast cancer covering 2/3 of the Swedish population. Information on HRT sales was obtained from national pharmacy data. The prevalence of HRT use in age group 50-59 years decreased from a peak of 36% in 1999 to 27% in 2002 and further to 9% in 2007. Incidence rates of breast cancer in women 50 years and older increased between 1997 and 2003. A significant decrease in incidence between 2003 and 2007 was confined to women 50-59 years of age, the group in which the prevalence of HRT use has been highest and the decrease in use most pronounced. As opposed to the immediate effects reported from the United States and other regions, there was a time lag between the drop in HRT use and clear reductions in breast cancer incidence. This may reflect between country differences with regard to types of HRT used, and the rate, magnitude and pattern of change in use. The present findings give further support to the notion that HRT use is a driver of breast cancer incidence trends on the population level.

Entities:  

Mesh:

Year:  2009        PMID: 19894110     DOI: 10.1007/s10549-009-0615-7

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  8 in total

1.  Changes in invasive breast cancer and ductal carcinoma in situ rates in relation to the decline in hormone therapy use.

Authors:  Ghada N Farhat; Rod Walker; Diana S M Buist; Tracy Onega; Karla Kerlikowske
Journal:  J Clin Oncol       Date:  2010-11-08       Impact factor: 44.544

2.  Understanding recent trends in incidence of invasive breast cancer in Norway: age-period-cohort analysis based on registry data on mammography screening and hormone treatment use.

Authors:  Harald Weedon-Fekjær; Kjersti Bakken; Lars J Vatten; Steinar Tretli
Journal:  BMJ       Date:  2012-01-30

3.  Epidemiologic patterns of injuries treated at the emergency department of a Swedish medical center.

Authors:  Fredrik Röding; Marie Lindkvist; Ulrica Bergström; Jack Lysholm
Journal:  Inj Epidemiol       Date:  2015-01-30

Review 4.  Menopausal Hormone Therapy, Age, and Chronic Diseases: Perspectives on Statistical Trends.

Authors:  Judy L Bolton
Journal:  Chem Res Toxicol       Date:  2016-09-26       Impact factor: 3.739

5.  Recent hip fracture trends in Sweden and Denmark with age-period-cohort effects.

Authors:  B E Rosengren; J Björk; C Cooper; B Abrahamsen
Journal:  Osteoporos Int       Date:  2016-09-19       Impact factor: 4.507

6.  Gynecologists are afraid of prescribing hormone replacement to endometrial/ovarian cancer survivors despite national guidelines-a survey in Sweden.

Authors:  Sandra Halldorsdottir; Hanna Dahlstrand; Karin Stålberg
Journal:  Ups J Med Sci       Date:  2018-12-10       Impact factor: 2.384

7.  Changing patterns in the clinical characteristics of korean breast cancer from 1996-2010 using an online nationwide breast cancer database.

Authors:  Beom Seok Ko; Woo Chul Noh; Sung Soo Kang; Byeong Woo Park; Eun Young Kang; Nam Sun Paik; Jung Hyun Yang; Sei Hyun Ahn
Journal:  J Breast Cancer       Date:  2012-12-31       Impact factor: 3.588

8.  Postmenopausal hormone therapy and the risk of rheumatoid arthritis: results from the Swedish EIRA population-based case-control study.

Authors:  Cecilia Orellana; Saedis Saevarsdottir; Lars Klareskog; Elizabeth W Karlson; Lars Alfredsson; Camilla Bengtsson
Journal:  Eur J Epidemiol       Date:  2015-03-12       Impact factor: 8.082

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.